Form 4: Prelude Therapeutics Executive Jane Huang Reports Stock Transactions
SEC Form 4
Jane Huang, President and CMO of Prelude Therapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On April 4, 2024, Jane Huang, President and CMO of Prelude Therapeutics, engaged in transactions involving the company's common stock.
- Huang vested 9,375 restricted stock units (RSUs), each representing a contingent right to receive one share of Prelude Therapeutics' common stock.
- The company withheld 3,347 shares to satisfy tax withholding obligations related to the RSU vesting at a price of $4.74 per share.
- Following these transactions, Huang directly owns 51,287 shares of Prelude Therapeutics common stock and 75,000 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine transaction report, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting insider transactions. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the vesting of previously granted equity compensation.
Key Dates
| Date | Description |
|---|---|
| May 2, 2022 | RSUs were granted to Jane Huang. |
| April 4, 2023 | 1/4 of the total shares of RSUs vested. |
| April 4, 2024 | RSUs vested and shares were withheld for tax obligations; report date of transactions. |
| April 8, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.